Unlike large pharma where novel projects compete with established, safer alternatives, biotech startups derive immense power from their singular focus. The "live or die" mentality on a single hard problem forces teams to innovate and persevere through setbacks, which is essential for pushing true scientific boundaries.

Contrary to startup culture, the best training for biotech leadership is gaining broad, cross-functional experience in a large, structured pharmaceutical company. This foundation provides the necessary depth and breadth to navigate the complexities of leading a smaller, resource-constrained biotech later on.

The transition from a leadership role at a large pharma company like Gilead to a biotech CEO involves a massive shift in scope. Instead of managing one large function with a large team, a biotech CEO is hands-on with every aspect of the company, from science to finance.

Lacking capital, Derek Small was forced to personally write grants and lead regulatory affairs. This hands-on, "virtual company" approach, born of necessity, gave him a profound, holistic understanding of the science and operations he wouldn't have gained otherwise.

While startups must be nimble, analytical processes from large corporations are invaluable. The key is applying the same rigorous thinking to decision-making but compressing the timeline. Having prior experience with similar situations allows leaders to make informed choices more quickly.

Ron Cooper credits his success not to being a "scaling guy" at Bristol-Myers Squibb, but the "fix-it guy." Being deployed to turn around struggling business units across different geographies and therapeutic areas provided the multicultural, problem-solving toolkit essential for navigating the constant challenges of leading a biotech startup.

The transition from a resource-rich environment like Novartis to an early-stage biotech reveals a stark contrast. The unlimited access to a global organization is replaced by a total reliance on a small, nimble team where everyone must be multi-skilled and hands-on, a change even experienced executives find jarring.

Tosh Butt describes his move from AstraZeneca to biotech as seeking the thrill of building from scratch without a corporate cushion. In Big Pharma, failure means a new project; in a startup, the clinical trial is the entire company. This mindset is crucial for biotech leaders.

A critical mindset shift from academia to startups is embracing the "killer experiment." Academics may fear an experiment that disproves a long-held hypothesis. In contrast, biotech startups, with finite capital, must run these experiments early to either validate or kill a program, efficiently allocating resources to viable projects.